Trials / Completed
CompletedNCT02744664
Cryotherapy Combine Icotinib for Advanced NSCLC Treatment
A Single Arm, Open Label, Perspective Study to Determine the Efficacy and Safety of Icotinib Combine Cryotherapy for Advanced NSCLC Patients
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Fuda Cancer Hospital, Guangzhou · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This trial is to designed to assess the efficacy and safety of Cryotherapy combine with Icotinib for Advanced NSCLC Patients harboring EGFR mutation.
Detailed description
In this single arm clinical study, enrolled patients, with advanced stage NSCLC and confirmed epidermal growth factor receptor (EGFR) mutation, would receive cryotherapy for tumors and begin Icotinib, an EGFR tyrosine kinase inhibitor administration thereafter. Progression free survival, overall survival and safety wil be observed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Cryotherapy | After entering the group subject receive Cryotherapy on lung cancer |
| DRUG | Icotinib | After Cryotherapy, subjects begin Icotinib administration |
Timeline
- Start date
- 2016-04-01
- Primary completion
- 2017-08-15
- Completion
- 2017-08-15
- First posted
- 2016-04-20
- Last updated
- 2020-05-27
Source: ClinicalTrials.gov record NCT02744664. Inclusion in this directory is not an endorsement.